INTRODUCTION {#sec1-1}
============

Prostate cancer (PCa) is the second most common cancer and the fifth leading cause of cancer deaths in males around the world, with 1 276 106 diagnosed cases and 358 989 deaths worldwide in 2018,[@ref1] accounting for a greater global burden of cancer than that in 2012.[@ref2] High-risk PCa, defined as prostate-specific antigen (PSA) \>20 ng ml^−1^ or Gleason score \>7 or clinical stage (T) \>T2c according to the 2018 European Association of Urology (EAU) guidelines, accounts for 15% of the confirmed cases.[@ref3] Definitive external beam radiotherapy (EBRT) with or without androgen deprivation therapy (ADT) and radical prostatectomy (RP) with or without adjuvant therapies are two common treatment options for patients with high-risk PCa. We designated them as EBRT-based therapy and RP-based therapy. Because high-risk PCa is prone to recurrence and metastasis after treatment, an increasing number of studies have focused on this issue in recent years. To date, only a few studies comparing EBRT-based therapy and RP-based therapy have been published, and the majority are small studies with conflicting results or that lack adequate follow-up periods. Due to the lack of solid evidence, the current guidelines do not provide clear recommendations with regard to patient selection criteria for each treatment. It is still uncertain as to which therapy is better for high-risk patients in terms of efficacy. Through a comprehensive database search, we only identified three systematic reviews focused on localized PCa or locally advanced PCa[@ref4][@ref5][@ref6] and two systematic reviews of high-risk prostate cancer published in 2014 and 2015, respectively.[@ref7][@ref8] Since then, several new studies on this topic have been published; we therefore systemically searched and analyzed the available literature to evaluate the efficiency of EBRT-based therapy compared with RP-based therapy using more comprehensive outcome measures including biochemical relapse-free survival (bRFS), cancer-specific survival (CSS), and overall survival (OS).

MATERIALS AND METHODS {#sec1-2}
=====================

 {#sec2-1}

### Search strategy {#sec3-1}

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement,[@ref9] we conducted a search using various combinations of Medical Subject Headings (MeSH) for "prostatic neoplasms," "prostatectomy," "radiotherapy," and "cohort studies," as well as non-MeSH terms for "radical prostatectomy," "prostate cancer surgery," "radiotherapy," "outcome," "survival/mortality," and "androgen deprivation therapy." PubMed, Embase, and Cochrane Central Register of Controlled Trials databases were searched for studies indexed from January 1, 1998, to April 30, 2019, with no limitation on the publication language. As a supplement, we also contacted some authors for study details. Following the literature search, all duplicates were excluded in Endnote and retrieved publications were subject to initial assessment of the title or abstract. Publications of radiotherapy only with brachytherapy were excluded. To ensure comprehensive coverage, references from included studies, review articles, editorials, commentaries, and conference publications were reviewed and cross-referenced. The computerized search was executed by investigators independently. Any discrepancy was resolved by consensus, with the participation of an interinvestigator.

### Data extraction {#sec3-2}

Two reviewers collected data independently using predesigned abstraction forms. When there were disagreements in data extraction, a consensus was achieved with a third reviewer. Variables including the first author, study characteristics, participant characteristics, and survival outcomes were extracted and are summarized in **[Table 1](#T1){ref-type="table"}**.

###### 

Characteristics of included studies

  Study                             Country (study interval)   Inclusion criteria (PSA, ng ml^−1^)   Median follow-up (EBRT vs RP, month)   Study size (EBRT vs RP, n)   Median age (EBRT vs RP, year)   Adjuvant therapies (EBRT vs RP, %)                                                Salvage therapies (EBRT vs RP, %)                              Outcome
  --------------------------------- -------------------------- ------------------------------------- -------------------------------------- ---------------------------- ------------------------------- --------------------------------------------------------------------------------- -------------------------------------------------------------- ---------------
  Akakura *et al*.[@ref15] 1999     Japan (1989--1993)         B2 and C^\*^                          58.5 versus 58.5                       46 versus 49                 68.7 versus 68.1                ADT: 100.0 versus 100.0                                                           --                                                             CSS
  Saito *et al*.[@ref23] 2006       Japan (1992--2003)         T3, any GS                            55.0 versus 55.0                       78 versus 30                 69.3 versus 64.0                ADT: 100.0 versus 100.0                                                           --                                                             CSS, OS
  Arcangeli *et al*.[@ref16] 2009   Italy (2003--2007)         GS ≥8 or PSA \>20 or T ≥T3            38.6 versus 33.8                       162 versus 122               75.0 versus 65.5                ADT: 100.0 versus -; EBRT: 0 versus 68.0                                          --                                                             bRFS
  Boorjian *et al*.[@ref19] 2011    USA (1988--2004)           PSA ≥20 or T ≥T3 or GS ≥8             72.0 versus 122.4                      344 versus 1238              68.8 versus 66.0                ADT: 56.5 versus 29.6; EBRT: 0 versus 6.9; Both: 0 versus 4.1                     ADT: 16.6 versus 0; EBRT: 0 versus 20.4                        CSS, OS
  Kevin *et al*.[@ref31] 2013       USA (1996--2010)           PSA ≥20 or T ≥T3 or GS ≥8             53.3 versus 53.3                       655 versus 900               67.9 versus 61.4                ADT: 99.0 versus 25.0                                                             --                                                             bRFS
  Lee *et al*.[@ref22] 2014         Korea (1996--2009)         PSA ≥20 or T ≥T3 or GS ≥8             76.0 versus 76.0                       125 versus 251               68.6 versus 67.5                ADT: 100.0 versus 0                                                               EBRT: 0 versus 10.4                                            CSS
  Koie *et al*.[@ref21] 2014        Japan (2004--2012)         PSA ≥20 or T=T2c, T3 or GS ≥8         37.6 versus 31.5                       78 versus 78                 73.5 versus 71.0                ADT: 100.0 versus 100.0                                                           --                                                             bRFS, OS
  Yamamoto *et al*.[@ref24] 2014    Japan (1994--2005)         T3                                    85.0 versus 93.0                       119 versus 112               72.0 versus 67.0                ADT: 95.8 versus 76.8                                                             ADT: 26.9 versus 31.2; EBRT: 0 versus 4.5                      CSS, OS
  Yamamoto *et al*.[@ref25] 2016    Japan (2007--2013)         PSA ≥20 or T=T3a or GS ≥8             54.5 versus 59.1                       43 versus 71                 73.0 versus 70.0                ADT: 100.0 versus 0                                                               ADT: -; EBRT: 0 versus -                                       bRFS
  Baker *et al*.[@ref17] 2016       USA (2001--2014)           GS ≥8                                 61.0 versus 61.0                       71 versus 50                 69.6 versus 60.9                ADT: 95.8 versus 36.0; EBRT: 0 versus 44.0                                        EBRT: - versus 27.0                                            bRFS
  Kishan *et al*.[@ref20] 2017      USA (2000--2013)           GS 9--10                              50.4 versus 58.8                       230 versus 170               69.9 versus 61.9                ADT: 93.9 versus 0; EBRT: 0 versus 12.3; NAST: 0 versus 10.6; AST: 0 versus 7.1   ADT: 19.7 versus 30.1; EBRT: 0 versus -; LT: 0.9 versus 42.9   bRFS, CSS, OS
  Ciezki *et al*.[@ref18] 2017      USA (1996--2012)           PSA ≥20 or T ≥T3 or GS ≥8             63.5 versus 63.5                       734 versus 1308              68.5 versus 62.0                ADT: 93.0 versus 19.0                                                             --                                                             bRFS, CSS
  Johnstone *et al*.[@ref26] 2006   USA (1995--2001)           T4 or N1, M0                          --                                     257 versus 72                66.8 versus 64.3                ADT: 100.0 versus 0                                                               --                                                             OS
  Kim *et al*.[@ref27] 2014         Korea (2001--2011)         PSA ≥20 or T ≥T3 or GS ≥8             48.7 versus 48.8                       109 versus 200               71.0 versus 66.0                ADT: 59.0 versus 27.0                                                             --                                                             bRFS, CSS, OS
  Kishan *et al*.[@ref28] 2018      USA 2000--2013             GS 9--10                              61.2 versus 50.4                       734 versus 639               67.7 versus 61.0                ADT: 89.5 versus 0; EBRT: 0 versus 8.7; NAST: 0 versus 19.0; AST: 0 versus 11.3   LT: 2.5 versus 34.1; ST: 12.1 versus 24.1                      CSS, OS
  Markovina *et al*.[@ref29] 2017   USA (2002--2011)           PSA ≥20 or T ≥T3 or GS≥8              51.4 versus 41.0                       62 versus 62                 64.2 versus 62.9                ADT: 80.6 versus 6.5                                                              --                                                             OS
  Reichard *et al*.[@ref30] 2018    USA (2004--2013)           --                                    61.0 versus 61.0                       74 versus 231                66.2 versus 61.2                ADT: 100.0 versus 0                                                               --                                                             bRFS

^\*^Whitmore--Jeweet staging system, PCa of B2 and C can be classified as high-risk PCa according to EAU guidelines (T≥T2c). NAST: neoadjuvant systemic therapy; AST: adjuvant systemic therapy; LT: local therapy; ST: systemic therapy; GS: Gleason score; EBRT: external beam radiotherapy; RP: radical prostatectomy; ADT: androgen deprivation therapy; PSA: prostate-specific antigen; bRFS: biochemical relapse-free survival; CSS: cancer-specific survival; OS: overall survival; TNM: tumor node staging; T: tumor (clinical stage of TNM staging system); PCa: prostate cancer; --: not available.

### Outcome measures {#sec3-3}

High-risk PCa was defined as PSA \>20 ng ml^−1^ or Gleason score \>7 or T \>T2c according to the EAU guidelines. Biochemical recurrence in RP patients was defined as postoperative PSA ≥0.2 ng ml^−1^ or at initiation of salvage RT or salvage ADT. Biochemical recurrence in EBRT patients was defined as PSA ≥ nadir +2 ng ml^−1^ or at initiation of local salvage or salvage ADT. We chose bRFS, CSS, and OS as the endpoints of this study. The primary outcomes of this analysis were the effects of RP-based therapy on bRFS, CSS, and OS and the effects of EBRT-based therapy on bRFS, CSS, and OS. For studies that reported hazard ratio (HR), the adjusted HRs were extracted. For other studies that did not report HR, we first processed the survival curves with Engauge Digitizer 4.1 (UpdateStar, Berlin, Germany) and then calculated HRs of each outcome according to the widely used method that Tierney *et al*.[@ref10] reported.

### Statistical analyses {#sec3-4}

HRs were used to analyze survival outcomes. Extracted data were pooled into the meta-analysis by Review Manager (RevMan) software version 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark). We calculated the estimated effects of the two treatments on survival outcomes by log(HR) and standard error (s.e.). Between-study heterogeneity was identified by the *Q*-test and then estimated by the DerSimonian--Laird method and quantified by *I*^2^ values.[@ref11] We employed the random effects models for each of our analyses, under which we assumed that the true effect size might differ from study to study. Then, we ran an influence diagnostic for each outcome measure. Given the identified clinical heterogeneity, subgroup analyses were performed. We assessed publication bias using funnel plots and used Egger\'s test to statistically examine the funnel plot asymmetry.[@ref12]

### Quality assessment {#sec3-5}

Two independent reviewers assessed the methodological quality of the included randomized controlled trial (RCT) by Jadad Scale,[@ref13] and the methodological quality of retrospective studies was assessed according to the Newcastle--Ottawa Scale. This scale assesses the risk of bias in three domains: (1) selection of the study groups, (2) comparability of groups, and (3) ascertainment of exposure and outcome.[@ref14] Studies were considered as having a low risk of bias (overall scores \>7), moderate risk of bias (overall scores 4--6), and high risk of bias (overall scores \<4). According to our assessment, the follow-up duration was adequate if the median or mean follow-up was more than 5 years.

RESULTS {#sec1-3}
=======

 {#sec2-2}

### Search results {#sec3-6}

A flowchart of the literature search is shown in **[Figure 1](#F1){ref-type="fig"}**. The primary database search resulted in 4890 records, from which 1660 duplicated records were excluded. A total of 3057 records were excluded following the title and abstract review. Of the 173 articles subjected to full-text assessment, 156 studies were excluded: 38 were review articles; 7 were from duplicate study cohorts; 37 reported unrelated exposure or outcomes; 47 involved incomparable patient populations; and 27 articles were case reports, letters, or editorial comments. In total, 17 publications involving 9504 patients were included.[@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31]

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram outlining the search strategy and final included and excluded studies. CENTRAL: Cochrane Central Register of Controlled Trials databases.](AJA-22-383-g001){#F1}

### Characteristics and quality of studies {#sec3-7}

Of the 9504 included patients (**[Table 1](#T1){ref-type="table"}**), 3921 (41.3%) underwent EBRT-based treatment. ADT was administered to 3717 (94.8%) of the 3921 patients receiving EBRT-based treatment. In addition, 286 (7.3%) patients received salvage therapies, among which 177 (4.5%), 20 (0.5%), and 89 (2.3%) received salvage ADT, salvage local therapy, and salvage systemic therapy, respectively. Moreover, patients treated with EBRT-based treatment were generally older compared with patients treated with RP-based treatment in all of the included studies.

The remaining patients received RP-based treatment. Adjuvant ADT, adjuvant EBRT, and adjuvant systemic therapy were given to selected patients; however, we were unable to extract the exact number of patients under each therapy due to the lack of treatment details in the articles. In addition, some patients received salvage therapies after RP, such as salvage ADT (9.0%), salvage EBRT (not available), salvage local therapy (5.2%), and salvage systemic therapy (2.8%).

Duration of follow-up and inclusion criteria varied from study to study (**[Table 1](#T1){ref-type="table"}**). The definition of high-risk PCa has changed over time; however, all the included patients were diagnosed with high-risk PCa according to the 2018 EAU guidelines. We excluded studies that assessed the efficacy of EBRT-based treatment with patients treated with brachytherapy. Ten studies[@ref15][@ref16][@ref17][@ref19][@ref21][@ref22][@ref24][@ref25][@ref27][@ref28] provided data of EBRT modality, such as conventional EBRT, three dimensional conformal radiation therapy, and intensity modulated radiation therapy. Radiation dosage was only mentioned in 15[@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref27][@ref28][@ref29][@ref31] of 17 studies and mostly ranged from 60 to 80 gray (Gy, J kg^−1^). In addition, considerable variability was found in the use of adjuvant or salvage therapies, regardless of the modality or duration.

Of the 17 studies included, 16 were retrospective[@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31] and one was a RCT.[@ref15] The RCT scored three out of five points (considered as high quality) according to the Jadad Scale. None of the retrospective studies were considered as low quality with a high risk of bias according to the Newcastle--Ottawa Scale assessment (**[Table 2](#T2){ref-type="table"}**).

###### 

Newcastle--Ottawa Scale for risk of bias assessment of studies included in the meta-analysis

  Study                             Selection   Comparability   Outcome   Total                   
  --------------------------------- ----------- --------------- --------- ------- --- --- --- --- ---
  Saito *et al*.[@ref23] 2006       1           1               1         1       2   1   1   1   9
  Arcangeli *et al*.[@ref16] 2009   1           1               1         1       1   1   0   1   7
  Boorjian *et al*.[@ref19] 2011    1           1               1         1       2   1   1   1   9
  Kevin *et al*.[@ref31] 2013       1           1               1         1       2   1   1   0   8
  Lee *et al*.[@ref22] 2014         1           1               1         1       2   1   1   1   9
  Koie *et al*.[@ref21] 2014        1           1               1         1       2   1   0   1   8
  Yamamoto *et al*.[@ref24] 2014    1           1               1         1       1   1   1   1   8
  Yamamoto *et al*.[@ref25] 2016    1           1               1         1       1   1   1   1   8
  Baker *et al*.[@ref17] 2016       1           1               1         1       1   1   1   1   8
  Kishan *et al*.[@ref20] 2017      1           1               1         1       1   1   1   1   8
  Ciezki *et al*.[@ref18] 2017      1           1               1         1       1   1   1   1   8
  Johnstone *et al*.[@ref26] 2006   1           1               1         1       1   1   0   1   7
  Kim *et al*.[@ref27] 2014         1           1               1         1       1   1   0   1   7
  Kishan *et al*.[@ref28] 2018      1           1               1         1       1   1   0   1   7
  Markovina *et al*.[@ref29] 2017   1           1               1         1       2   1   0   1   8
  Reichard *et al*.[@ref30] 2018    1           1               1         1       1   1   1   0   7

### bRFS of EBRT-based treatment versus RP-based treatment {#sec3-8}

Eight studies[@ref16][@ref17][@ref18][@ref20][@ref21][@ref25][@ref27][@ref30] with a total of 3701 patients were involved in the assessment. Meta-analysis showed that the patients might benefit from EBRT-based treatment with a lower risk of biochemical failure (**[Figure 2a](#F2){ref-type="fig"}**). There was significant heterogeneity among the studies (**[Figure 2a](#F2){ref-type="fig"}**). Due to the small number of studies in the meta-analysis, we were unable to perform subgroup analyses or fit a mixed effects model with potential sources of heterogeneity as the covariates. Leave-one-out analysis showed that the direction and magnitude of HRs were quite consistent after removing any study in the analysis (**Supplementary Figure 1a**).

![Forrest plot and funnel plot assessing the risk of (**a**) bRFS, (**b**) CSS, and (**c**) OS following EBRT-based and RP-based treatment. CI: confidence interval; EBRT: external beam radiotherapy; RP: radical prostatectomy; HR: hazard ratio; bRFS: biochemical relapse-free survival; CSS: cancer-specific survival; OS: overall survival.](AJA-22-383-g002){#F2}

### CSS of EBRT-based treatment versus RP-based treatment {#sec3-9}

Nine studies[@ref15][@ref18][@ref19][@ref20][@ref22][@ref23][@ref24][@ref27][@ref28] with a total of 6516 patients were aggregated to assess the effects of treatment modality on CSS. We did not observe significant differences in CSS between EBRT-based treatment and RP-based treatment (**[Figure 2b](#F2){ref-type="fig"}**). There was significant heterogeneity among the studies (**[Figure 2b](#F2){ref-type="fig"}**). Subgroup analyses should be performed to determine the sources of heterogeneity or a mixed effects model can be fitted with these factors as covariates. However, we did not have enough studies for further assessment. The leave-one-out analysis showed that the studies conducted by Lee *et al*.[@ref22] and Kishan *et al*.[@ref28] had the greatest impacts on the HR estimates, and the result was significant after removing the study conducted by Kishan *et al*.[@ref28] mainly because they employed local and systematic treatment as adjuvant or salvage therapy (**Supplementary Figure 1b**).

### OS of EBRT-based treatment versus RP-based treatment {#sec3-10}

When nine studies[@ref19][@ref20][@ref21][@ref23][@ref24][@ref26][@ref27][@ref28][@ref29] on 4612 patients were pooled, EBRT-based treatment was associated with a significantly increased risk of overall mortality compared with RP-based treatment (**[Figure 2c](#F2){ref-type="fig"}**). There was no significant heterogeneity among the studies (**[Figure 2c](#F2){ref-type="fig"}**). In addition, the leave-one-out analysis showed that the direction and magnitude of HR were quite consistent after removing any study in the analysis (**Supplementary Figure 1c**).

### Influence diagnostics {#sec3-11}

Influence diagnostics were conducted for three outcomes (**Supplementary Figure 1**). For bRFS, Ciezki *et al*.[@ref18] had a large influence on the model fit and was considered as an outlier. Removal of this study would significantly reduce the amount of heterogeneity. For CSS, Lee *et al*.[@ref22] and Kishan *et al*.[@ref28] had a large influence on the model fit and Lee *et al*.[@ref22] was considered an outlier. Removing the two studies would significantly reduce the amount of heterogeneity. For OS, Boorjian *et al*.[@ref19] and Kishan *et al*.[@ref28] had a large influence on the model fit and Kishan *et al*.[@ref28] was considered an outlier.

### Publication bias {#sec3-12}

Funnel plot and Begg\'s test were used to assess publication bias. The funnel plot was quite symmetrical (**[Figure 2](#F2){ref-type="fig"}**), indicating the absence of publication bias in the present meta-analysis. Egger\'s test again supported the conclusion for bRFS (*P* = 0.6789), CSS (*P* = 0.7111), and OS (*P* = 0.9506).

DISCUSSION {#sec1-4}
==========

Unlike low-risk localized PCa, there is no established treatment option for high-risk PCa patients. The widely performed treatment options for high-risk PCa include EBRT-based treatment (mostly plus ADT) and RP-based treatment. However, the current guidelines from the EAU, the American Urological Association (AUA), and the National Comprehensive Cancer Network (NCCN)[@ref32] are inconsistent with regard to which treatment should be used as the first-line treatment for high-risk PCa. In the current meta-analysis, the definition of high-risk PCa varied considerably in the included 17 studies, but all of them met the criteria of the 2018 EAU guidelines.

By reviewing and summarizing the 17 previously published studies with low-to-moderate risk of bias, we identified that EBRT-based treatment was associated with better bRFS than RP-based treatment. Conversely, RP-based treatment was associated with a significantly better OS than EBRT-based treatment. Moreover, the analysis showed no statistically significant difference between the two treatments in terms of CSS, which is in contradiction with a previous meta-analysis.[@ref7] It suggested that EBRT-based treatment might be associated with a higher risk of cancer-specific mortality after controlling for related bias. Thus, more studies need to be included in this analysis. In addition, we have compared the two treatment modalities by the 5-year bRFS rates, the 5-year CSS rates, and the 5-year OS rates; most studies reported better 5-year CSS rates, better 5-year OS rates, and worse 5-year bRFS rate for RP-based treatment (**[Table 3](#T3){ref-type="table"}**).

###### 

Absolute 5-year survival rates for included studies

  Study                             5-year bRFS (%)   5-year CSS (%)   5-year OS (%)                  
  --------------------------------- ----------------- ---------------- --------------- ------ ------- ------
  Akakura *et al*.[@ref15] 1999     --                                 84.6            96.6   --      --
  Saito *et al*.[@ref23] 2006       --                --               96.6            93.8   94.9    87.3
  Arcangeli *et al*.[@ref16] 2009   74.6              54.2             --              --     --      --
  Boorjian *et al*.[@ref19] 2011    --                --               96.0            97.3   88.2    92.3
  Kevin *et al*.[@ref31] 2013       74.0              61.0             --              --     --      --
  Lee *et al*.[@ref22] 2014         --                --               88.3            96.5   --      --
  Koie *et al*.[@ref21] 2014        78.8              81.8             --              --     92.3    98.6
  Yamamoto *et al*.[@ref24] 2014    --                --               85.7            93.1   79.9    96.6
  Yamamoto *et al*.[@ref25] 2016    20.9              59.2             --              --     --      --
  Baker *et al*.[@ref17] 2016       92.8              57.7             --              --     --      --
  Kishan *et al*.[@ref20] 2017      71.9              26.4             91.6            91.7   79.9    90.3
  Ciezki *et al*.[@ref18] 2017      74.0              65.0             94.7            97.2   --      --
  Johnstone *et al*.[@ref26] 2006   --                --               --              --     72.6    71.1
  Kim *et al*.[@ref27] 2014         82.0              30.4             94.8            96.3   84.4    94.4
  Kishan *et al*.[@ref28] 2018      --                --               87.0            88.0   82.0    83.0
  Markovina *et al*.[@ref29] 2017   79.0              42.0             --              --     81.0    86.1
  Reichard *et al*.[@ref30] 2018    33.0              2.0              --              --     100.0   94.0

EBRT: external beam radiotherapy; RP: radical prostatectomy; bRFS: biochemical relapse-free survival; CSS: cancer-specific survival; OS: overall survival; --: not available.

After a thorough search of published meta-analyses on this topic, our study represents the most comprehensive and up-to-date review. There were three previous meta-analyses[@ref4][@ref5][@ref6] examining the survival outcomes among patients with localized or locally advanced PCa treated with surgery or radiotherapy. Lei *et al*.[@ref8] conducted a meta-analysis comparing the survival outcomes among patients with high-risk PCa treated with RP, EBRT, brachytherapy, ADT, and watchful waiting, which revealed that RP or (EBRT plus ADT) gave the best prognosis in patients with high-risk PCa. Furthermore, RP had significantly better OS and CSS than EBRT (with or without ADT). Another meta-analysis conducted by Petrelli *et al*.[@ref7] also found better OS and CSS for patients treated with RP compared with EBRT; however, the odds ratios (OR) they used had natural limitations compared with the time-to-event outcome measures in our study. In addition, by including higher-quality studies published in recent years, we have updated the two meta-analyses in high-risk patients and added another outcome measure for bRFS.

Evidence of significant between-study heterogeneity was identified in the statistics for our pooled analysis of bRFS and CSS. The potential source of heterogeneity might be mainly differences in study design, baseline characteristics, and treatment modality. The studies that caused more heterogeneity were identified through the influence diagnostics. Among the included studies, the surgical approach, EBRT dosage, and modality varied, and the use of adjuvant or salvage therapy also differed. In addition, the duration and drug category of the adjuvant ADT or salvage ADT was diverse, further complicating the potential source of heterogeneity.

It is unclear why the EBRT group showed better bRFS and the RP group showed better OS. Potential explanations include: (1) patients receiving EBRT were generally older than those undergoing RP, and age could be a risk factor for comorbidities and worse OS; (2) patients who initially received RP still had the chance to undergo salvage EBRT, while those who have undergone EBRT rarely received salvage RP even if the treatment failed, and the relatively high biochemical recurrence rate after RP might account for the higher use of salvage therapies; (3) EBRT and ADT drugs have greater toxicity and long-term side effects, which might contribute to the worse OS of EBRT-based treatment; (4) surgery could reduce a greater tumor burden than EBRT, which might account for the better OS; (5) postradiotherapy patients are diagnosed as a biochemical failure with a higher PSA level and are often given a longer duration of ADT; therefore, the EBRT group would show better bRFS.

In this study, we performed a comprehensive search of published studies, undertook a careful selection of studies, and conducted strict quality assessment of included studies to draw robust conclusions comparing EBRT- and RP-based treatments. However, there are several limitations in our meta-analysis, including the lack of information on the methodological quality among the included studies, the significant between-study differences in treatment modality, and the small number of studies that limited our ability to assess the potential sources of heterogeneity. However, this meta-analysis, with nearly 10 000 patients, is the most up-to-date review analyzing the outcomes of high-risk PCa patients treated by EBRT- or RP-based treatment. The conclusion of this study is important for clinicians in choosing the best treatment plan for high-risk PCa patients.

CONCLUSION {#sec1-5}
==========

We identified better OS for RP-based treatment and better bRFS for EBRT-based treatment in high-risk PCa. RP-based treatment showed no significant superiority compared with EBRT-based treatment with regard to CSS. The results suggested that BP-based treatment would be more preferential for populations that valued longer survival, and EBRT-based treatment might be a promising alternative option for older populations. Large-scale RCT and observational studies with adequate duration of follow-up were needed to attain a comprehensive comparison between EBRT and RP for high-risk PCa.
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###### 

Influence diagnostics of (**a**) bRFS, (**b**) CSS, (**c**) OS. Influence diagnostics shows plots of the external standardized residuals; the DIFFITs values; the Cook\'s distances; the covariance ratios; the leave-one-out estimates of the amount of heterogeneity; the leave-one-out values of the test statistics for heterogeneity; the hat values; and the weights. bRFS: biochemical relapse-free survival; CSS: cancer-specific survival; OS: overall survival.
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